Hear Important Insights on the Early Access to Medicines Initiative and Discuss with Leading Experts

SMi Reports: Britain was looking to accelerate access to drugs for patients with rare diseases when it launched the Early Access to Medicines Initiative in March this year. This initiative will be extremely beneficial for patients.
 
 
P-118-150x150
P-118-150x150
 
Spread the Word
Listed Under

Tags:
* Orphan Drugs
* Rare Diseases
* Pharma
* Pharmaceutical
* Drug Development

Industry:
* Health

Location:
* London City - London, Greater - UK

LONDON - June 10, 2014 - PRLog -- SMi Reports: Britain was looking to accelerate access to drugs for patients with rare diseases when it launched the Early Access to Medicines Initiative in March this year. This initiative, which is similar to one in the U.S., will be extremely beneficial for patients and will also open up the market for pharmaceutical companies.

Based on this information SMi Group is proud to announce it will be hosting the 3rd annual conference on Orphan Drugs and Rare Diseases and bringing together leading experts from the MHRA and companies such as Novabiotics, Pfizer, AstraZeneca, GMP Orphan SAS, Genethon and M&C Saatchi and many more to discuss the latest developments in the market.

Benefits of Attending:

·         Hear important insights from Ian Hudson, CEO, MHRA on the Early Access to Medicines Initiative and adaptive licensing

·         Focus on enhancing development pathways, with the growth of the commercial pipeline for orphan drugs and rare diseases

·         Assess tools for consideration to gain early market access and enhance patient recruitment

·         Interactive round table discussion led by Dominic Nutt, Director of Communications, The Saatchi Cancer Initiative, M&C Saatchi on creating a culture of innovation in the field of orphan drugs and rare diseases

Key Speakers:

·         Dr Gunter Harms, Market Access & Public Affairs Directore, Shire

·         Bertram Haussle, Chaiman of the Board of Management, IGES Institut

·         Josie Godfrey, Associate Director-Highly Specialised Technologies, NICE

·         Chris Hart, Information Practice Leader, AstraZeneca

·         Anthony Hall, Co-Founder, Findacure Foundation

For more information please visit http://www.smi-online.co.uk/2014orphandrugs26.asp

If you would like to attend this conference as a delegate please contact John Collins on +44 (0) 207 827 6128 or e-mail amccann@smi-online.co.uk

If you are interested in sponsoring this event contact Alia Malick on +44(0)20 7827 6168 or email amalick@smi-online.co.uk

If you would like to become a media partner contact Sarah Watson on +44 (0)20 7827 6134 or email swatson@smi-online.co.uk

Contact
SMi Group Ltd
+4402078276128
swatson@smi-online.co.uk
End
Source:
Email:***@smi-online.co.uk Email Verified
Tags:Orphan Drugs, Rare Diseases, Pharma, Pharmaceutical, Drug Development
Industry:Health
Location:London City - London, Greater - United Kingdom
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SMi Group Ltd. News
Trending
Daily News
Weekly News



Like PRLog?
9K2K1K
Click to Share